CN100364606C - 肽组合物和制剂及其使用 - Google Patents
肽组合物和制剂及其使用 Download PDFInfo
- Publication number
- CN100364606C CN100364606C CNB998059390A CN99805939A CN100364606C CN 100364606 C CN100364606 C CN 100364606C CN B998059390 A CNB998059390 A CN B998059390A CN 99805939 A CN99805939 A CN 99805939A CN 100364606 C CN100364606 C CN 100364606C
- Authority
- CN
- China
- Prior art keywords
- sequence
- compositions
- peptide fragments
- peptide
- elastin peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 120
- 238000009472 formulation Methods 0.000 title abstract 3
- 102000016942 Elastin Human genes 0.000 claims abstract description 121
- 108010014258 Elastin Proteins 0.000 claims abstract description 121
- 229920002549 elastin Polymers 0.000 claims abstract description 121
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 38
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 38
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 108090001109 Thermolysin Proteins 0.000 claims description 11
- 210000004204 blood vessel Anatomy 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000002528 coronary thrombosis Diseases 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 95
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 21
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 3
- 238000007385 chemical modification Methods 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 91
- 235000001014 amino acid Nutrition 0.000 description 91
- 102000007547 Laminin Human genes 0.000 description 72
- 108010085895 Laminin Proteins 0.000 description 72
- 210000003491 skin Anatomy 0.000 description 55
- 210000001519 tissue Anatomy 0.000 description 32
- 239000004471 Glycine Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 21
- 239000012634 fragment Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003041 ligament Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000003796 beauty Effects 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108010029020 prolylglycine Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 3
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 3
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 3
- YTPLVNUZZOBFFC-SCZZXKLOSA-N Val-Gly-Pro Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N1CCC[C@@H]1C(O)=O YTPLVNUZZOBFFC-SCZZXKLOSA-N 0.000 description 3
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 229960002668 sodium chloride Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004227 thermal cracking Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 2
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 2
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 2
- NPLGQVKZFGJWAI-QWHCGFSZSA-N Phe-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O NPLGQVKZFGJWAI-QWHCGFSZSA-N 0.000 description 2
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- PPINMSZPTPRQQB-NHCYSSNCSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PPINMSZPTPRQQB-NHCYSSNCSA-N 0.000 description 1
- WOJJIRYPFAZEPF-YFKPBYRVSA-N 2-[[(2s)-2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]propanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)CN WOJJIRYPFAZEPF-YFKPBYRVSA-N 0.000 description 1
- HLPBVBAEIVCCLH-USJZOSNVSA-N 2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O HLPBVBAEIVCCLH-USJZOSNVSA-N 0.000 description 1
- FDJUEUDUCFJTBX-IYSQHNJGSA-N 2-aminoacetic acid (2S)-2-amino-3-methylbutanoic acid (2S,3S)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O.CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O FDJUEUDUCFJTBX-IYSQHNJGSA-N 0.000 description 1
- NUDSUGKLNRMFQF-TVKLMDQASA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid (2S)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.NCC(O)=O.OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CC1=CC=CC=C1 NUDSUGKLNRMFQF-TVKLMDQASA-N 0.000 description 1
- YBLDDXGNJXTBIA-YYCLPLPESA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid (2S)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CC1=CC=CC=C1 YBLDDXGNJXTBIA-YYCLPLPESA-N 0.000 description 1
- BXFCLVNVRLYXEP-RSLHMRQOSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.NCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O BXFCLVNVRLYXEP-RSLHMRQOSA-N 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 1
- KTNGVMMGIQWIDV-OSUNSFLBSA-N Ile-Pro-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O KTNGVMMGIQWIDV-OSUNSFLBSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 101000851074 Rattus norvegicus Elastin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- PMKQKNBISAOSRI-XHSDSOJGSA-N Val-Tyr-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N PMKQKNBISAOSRI-XHSDSOJGSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BLQCQNFLEGAHPA-RRKCRQDMSA-N [[(2r,3s,5r)-5-(5-bromo-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(Br)=C1 BLQCQNFLEGAHPA-RRKCRQDMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 108010043293 glycyl-prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010069589 glycyl-valyl-glycyl-valyl-proline Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 108010037335 tyrosyl-prolyl-glycyl-glycine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 108010072644 valyl-alanyl-prolyl-glycine Proteins 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Birds (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种用于增加组织的柔性、弹性或者表观的组合物。本发明尤其涉及基本上与热解消解弹性蛋白产物的肽相应的组合物制剂。所述制剂优选地以美容或者治疗制剂施用于人类皮肤。本发明的组合物特别包括本文所述的肽的公知的化学改性,尤其是羧基和氨基的改性,包括在肽片段两端的任一末端加合氨基酸。
Description
1.发明领域
本发明一般地涉及用于治疗或者美容的组合物。本发明的组合物特别适用于治疗组织。本发明的组合物优选地包括一或者多种肽,它们模拟弹性蛋白的作用,并且选择性地增加自身的弹性蛋白产生。优选地,基本氨基酸序列与哺乳动物弹性蛋白的部分相应或者同源,更优选地是与受治疗的哺乳动物的组织内源的弹性蛋白片段同源。优选的是,所述肽为有效治疗浓度的和/或药用的、治疗的或者美容的组合物的活性成分。更特别地,本发明涉及增加皮肤的弹性和丰满度的肽或者多肽。本发明的另一个方面是本发明的组合物的施用方法,以增加皮肤的弹性/或表观(例如,更光滑、更健康及更柔嫩)。
2.背景技术
皮肤,尤其是哺乳动物的皮肤,由数层细胞组成。哺乳动物皮肤的最外层称为角质层。此层保护哺乳动物的皮肤免受物理和大气的伤害,起对外部危害的屏障的作用。角质层的柔滑或纹理的程度直接取决于其水份。然而人们发现,在皮肤的深层,随老化出现的退行性改变主要不是由于缺乏水份造成的。因此,即使皮肤的纹理和外观取决于水分,但是其它的因素已经显示了对皮肤的整体外观和纹理的影响。例如,人们发现皮肤丧失弹性降低皮肤的色调和丰满度。据推测皮肤的色调和丰满度的降低是由皮肤中的某些复合的多肽的退化造成的。这些复合的多肽包括弹性蛋白和胶原等。
弹性蛋白是一种高度交联的复合多肽,是动物皮肤和结缔组织中的弹性纤维的主要成分。弹性蛋白对于组织的生理弹性似乎起主要的作用,正常的哺乳动物皮肤中,尤其是人类皮肤中,弹性组织蛋白占皮蛋白总量较少的部分,但是在保持和改善皮肤的色调和纹理方面起非常重要的作用。弹性蛋白本身是弹性纤维中的主要蛋白质物质,存在于腱、血管及结缔组织中。从这些组织中分离出以后,弹性蛋白一般为脆的、纤维性的、略带黄色的物质,不溶于水、醇和醚,但是在一定的程度上溶于碱金属氢氧化物溶液。致密交联的弹性蛋白结构使其非常难于增溶。为了增溶弹性蛋白并由增溶的弹性蛋白制造美容品,人们进行了多方的努力。例如美国专利4,327,078对增溶进行了尝试。但是发现弹性蛋白只是被皮肤略有吸收,且没有充分渗透进皮肤以对皮肤产生实质性的帮助。
本发明的概述
本发明涉及对其所施用的组织具有药用、治疗及/或美容作用的组合物。本发明的组合物优选地改变,或者说显得改变,其所施用的组织的物理特性,而且所述被改变的组织优选地是哺乳动物的皮肤组织。所述组合物一般地包括赋形剂或者载体,用于治疗性或者美容性的处理,其中肽配成有增加皮肤弹性的疗效的浓度。所述肽优选地溶于水溶液,且更优选地含有短的肽(一般长度少于约10个氨基酸)。优选地组合物的肽部分含有分子量低于10,000道尔顿的肽,更优选地含有90%分子量低于10,000道尔顿的肽。更优选地组合物的肽部分含有分子量低于3,000道尔顿的肽,再更加优选地含有分子量低于1,000道尔顿的肽。实际上,已发现本发明使用的肽的分子量优选地在约100-1,000道尔顿的范围,更优选地在约150-800道尔顿的范围;更优选地在约180-600道尔顿的范围;最优选地,所述治疗性或者美容性的组合物包括分子量约188-585道尔顿范围的肽。
人们还发现,最能够增加组织的弹性和丰满度的肽是那些与弹性蛋白的部分对应或者同源的肽,(尤其是受处理的组织内源性的弹性蛋白)。因此,我们发现弹性蛋白的消解,例如弹性蛋白水解或者用位点特异性的酶裂解产生特别适用于本发明的肽。消解产生的肽可以直接用于本发明的药用、治疗和/或美容性的制剂。本发明的肽也可以通过本领域内的一般技术人员公知的方法合成(即,固态的、液态的、及过度表达的)。术语“肽”用在本文并不是说要转达任何有关前体物质的意思,也不是指用于合成或者制造这些肽的方法。另外,术语“弹性蛋白的肽片段”,不论单肽或者多肽的形式,都是指所讨论的肽或者氨基酸序列相应于,或者生物等效于,或者实质上同源于弹性蛋白的一部分,或者更具体地说,受处理的动物的内源性弹性蛋白的一部分,或者片段。然而,术语“弹性蛋白肽片段”不意味要转达任何有关来源或者说起始物,或者任何得到弹性蛋白的肽片段的方法。如上所述,本发明的肽优选地由弹性蛋白的酶裂解形成,且更优选地由具有热解形成亲水性弹性蛋白衍生的肽的弹性蛋白的裂解形成。还优选地,本发明的肽在治疗或者美容品组合物内具有有效浓度,其中治疗有效浓度在约0.0002%至约90%重量的肽范围,更优选地在约0.05%至约50%的肽范围,再优选地在约0.5%至约10%的肽范围,还要优选地为约1.5%肽,最优选地为约1.3%水解的弹性蛋白肽。本发明的治疗组合物可以制成美容品制剂,用于局部施于患者的皮肤,例如在乳剂、洗液、喷雾剂、粉剂、油剂、膏剂剂或泡沫剂中,或者用于本领域内的一般技术人员普遍公知的其它给药形式(即,皮下)适当的药用赋形剂或者载体中。本发明的给药系统优选的是局部给药系统,但是也可以是皮下的、经皮的、口服、鼻吸、气溶胶或者贴片的给药系统。
本发明还涉及改善组织纹理的组合物,其中所述组合物含有通过选择性地裂解弹性蛋白形成的弹性蛋白肽。优选地,所述组合物包括一种给药系统,而且所述弹性蛋白由动物组织得到。经发现项韧带特别适合用作弹性蛋白起始原料。本发明的弹性蛋白优选有选择地用嗜热菌蛋白酶通过酶消解法裂解的弹性蛋白。这种热解裂解法优选地得到一种或多种弹性蛋白片段,其分子量约低于10,000道尔顿的肽,更优选地组合物的肽部分含有分子量低于3,000道尔顿的肽,再更加优选地含有分子量低于1,000道尔顿的肽。
本发明也涉及一种增强组织的功能性、色调、丰满度和/或弹性的方法,在所述的组织(尤其是皮肤组织)上给予有效治疗量的肽。在治疗皮肤时,改善了皮肤的外观,据认为这是改善了施加了肽的组织的弹性的结果。优选地,给药的步骤包括一些分开的给药步骤,它们最优选地在一个预定的时间内每天两次重复进行,其中所述预定的时间超过每天用肽用一周,更优选两周,最优选地,至少每天局部施用一个月(更优选地每天两次用一个月以上)。对于本发明的组合物,在本发明的方法中,优选地,所用的组合物包括具有分子量约低于1,000道尔顿的肽的一种弹性蛋白肽片段。优选并且方便地,所述肽可以通过弹性蛋白(优选地由动物组织得到)的酶裂解。优选地,所述酶裂解是用嗜热菌蛋白酶酶处理纯化的弹性蛋白起始物质而发生。
附图的简要说明
参照以下的说明、所附权利要求书,和附图,会更好地理解本发明的特点、方面和优点,其中:
图1为棒状图表,描述由于把本发明组合物用于哺乳动物皮肤引起的弹性蛋白产物的增加。
图2为显微照片,表示施用了本发明组合物的皮肤组织的微血管疗效。
优选实施方式的详细描述
为了充分理解本文说明的发明,在下面进行详细描述。本发明涉及适用于增加组织的弹性、丰满度和/或外观的组合物。
本发明还涉及所述组合物的给药治疗有效浓度。
在本文中,术语“对象”或者“患者”指的是任何哺乳动物,包括人类,其中弹性蛋白用于适当的组织机能或者外观。本文用的方法考虑保养、美容品和治疗的用途。
在本文中所用的术语“约”指的是所用的数字值的正负10%。因此约50%指从45%到55%的范围。在本文中所用的术语“道尔顿”指相当于氢原子质量(1.66×10-24克)的单位质量。一般讲,术语“组织”指任何相同地特异性细胞的集合,集中了特殊功能的特性。对于用到本文中,“组织”,除非另有所指,指的是包括弹性蛋白为其必要的结构和/或功能的部分的组织。例如结缔组织,除了其它物质之外,该组织由胶原纤维和弹性蛋白纤维构成,满足本文中所用的“组织”的定义。另外,弹性蛋白看来涉及血管、静脉、动脉在其固有的粘弹性方面的适当功能。除非另有所指,术语“皮肤”指身体的外层覆盖物或覆层,包括真皮和表皮,并且位于皮下组织上。
“提供”一词在与治疗关联使用时指的是直接向目标组织内或者上给药或者说向患者施以治疗,从而在治疗上正面地影响其目标组织(以保养、治疗或者美容的方式都可)。从而,在本文中使用时,术语“提供”在与弹性蛋白肽片段关联使用时,包括,但是不限于,向目标组织内或者上提供弹性蛋白肽片段;对患者全身地提供肽片段,例如通过皮内注射,从而使治疗到达目标组织;向目标组织提供其编码序列形式的弹性肽片段(例如,通过所谓基因治疗技术),从而在目标组织内表达弹性蛋白肽片段。
药品的配制和给药的详细技术可见于最新版的Remington’s Pharmaceutical Sciences(Mack Publishing Co,Easton Pa.)。尽管局部给药是合意的,还有其它的给药途径,例如口服、注射、气雾剂、肌肉、皮下、经皮、intamedullary、鞘内、心室内、静脉内、腹膜内或者鼻内给药。
在本文中使用时,术语“治疗”指的是用于处理、对抗、改善、防止或者改善患者的状况或者疾病。本发明中受治疗的状况是组织缺乏弹性蛋白,也就是说,组织中需要更多的弹性蛋白。在对皮肤施治时,由丰满度、色调、外观、皱纹程度和柔嫩度进行测定。在此术语用于血管时可以由血管的弹性程度或者适当的血管舒缩性反应(血管舒张/血管收缩)来测量。因此,血管的治疗处理可以涉及有关血管弹性的疾病,包括高血压、动脉粥样硬化、心绞疼、血管生成、心肌梗塞、冠状动脉栓塞、血管成形后再狭窄,以及慢性阻塞性肺血管病。
最后,本文中所用的术语“美容品”,指美化物或者制剂,它们保持、恢复、赋与、模拟或者加强形体美的外观,尤其是关系到组织或者皮肤的外观。
如上所述,本发明涉及一种弹性蛋白肽片段,它适用作治疗的或者美容品的组合物或制剂,用以修饰组织,特别是皮肤。术语“修饰”用于表达:通过将本发明的组合物提供、施加或者给药于所述组织而改变其外观、形状、特性和/或物理特征。形状的改变可以反映在以下的任何单一项或者数项的组合:改善皮肤的外观;增加皮肤的柔软度;增加皮肤的丰满度;增加皮肤的纹理;增加皮肤的弹性;减少皱纹并且增加皮肤中的内源的弹性蛋白产生。
起始弹性蛋白材料的来源可以从本领域内的一般技术人员公知的数种来源得到。例如项韧带大部分由弹性蛋白,只有相对较少量的胶原构成。此韧带的干重70%以上是弹性蛋白。因为较高的弹性蛋白含量和较低的胶原含量,项韧带是用于得到本发明的弹性蛋白肽片段的理想起始材料。项韧带可以先用类似美国专利5,028,695公开的方法清洁,此专利在本文引作参考。尽管本发明的起始原料的优选来源是项韧带,其它的韧带、腱、结缔组织、组织、以及合成来源也可以采用。例如可以采用动脉和肺,及其它动物组织,特别是那些有大量的弹性蛋白的组织。还有,从不同来源得到的弹性蛋白,或者从相同或不同来源得到的弹性蛋白及胶原可以混合在一起,以产生特别有优势的适用于特定的用途的混合物。例如,大鼠、绵羊及猫的大动脉可以用作弹性蛋白的来源,如L.B.Sandberg,在结缔组织研究(ConnectiveTissue Research),1990年,25卷,139-148页发表的论文所述,在此引为参考。
在本发明中,韧带提取物包含切碎的项韧带中取得的韧带,并且尽可能去掉大量脂肪和过量的结缔组织。然后把这些“清洁”的韧带切碎成约一平方厘米(1cm2)的片并用蒸馏水(DDW)清洗。把清洁的韧带置于一个金属臼中,预冷至-20,然后加液氮冷冻组织。然后用适当的工具把所述韧带切碎或者制成粉末,并再悬浮至1%的氯化钠水溶液中,比例为约每三升1%的氯化钠水溶液中约100克组织,并且在Waring匀浆机中以高速匀浆30-60秒。匀浆后的韧带移送到四升的烧杯中,在磁力搅拌器上于4℃下搅拌过夜,之后以32,500×G的离心力离心,然后检查上清液的蛋白含量,用缩二脲法进行蛋白确定。缩二脲反应通过把2毫升提取物与3毫升试剂混合进行,立即用视觉检查或者用比色计在540纳米外测定上清液的蛋白含量。然后丢弃上清液。把颗粒状物(后文称弹性蛋白颗粒状物)再悬浮于1%的氯化钠水溶液中并匀浆。匀浆过程在华林氏匀浆机中进行,搅拌过夜然后重复离心三至四遍直到上清澈缩二脲反应呈阴性。离心之后,把弹性蛋白颗粒状物再悬浮于蒸馏水中,以30psi的压力高压蒸六小时。把再悬浮的弹性蛋白颗粒状物再离心,然后用缩二脲法检查上清液的蛋白含量。用沸腾的蒸馏水洗弹性蛋白,然后用室温的蒸馏水洗弹性蛋白,用缩二脲法检查洗液的蛋白含量。如果洗液为缩二脲阴性,用氯仿/甲醇溶液干燥弹性蛋白颗粒状物,氯仿/甲醇的比是2比1。如果缩二脲试验阳性,重复六小时高压蒸洗过程,直到缩二脲反应阴性。最后用四体积的纯甲醇洗弹性蛋白,并于室温空气干燥。弹性蛋白剩余物移到干燥器中并且在P2O5下干燥24小时以上直到弹性蛋白的重量稳定。把弹性蛋白剩余物在威利氏实验室粉碎机中磨碎,经40目筛过筛,跟着经60目筛过筛。
对嗜热菌蛋白酶消解,使用CalBiochem公司(10394 Pacific CenterCourt,San Diego,CA92121)的三次再结晶的嗜热菌蛋白酶产品。嗜热菌蛋白酶制剂含有足够的钙以保证酶的最大活性。嗜热菌蛋白酶消解进行如下:用旋转摇床把水浴温度调整到55℃,并且在室温下把五克细磨的大量不可溶的弹性蛋白剩余物用一升蒸馏水水合15分钟。水合以后,把这一升含有五克弹性蛋白的蒸馏水置于55℃的水浴中,用10%的甲胺把弹性蛋白/水的混合物的pH值调节到7-3之间。五十毫克的嗜热菌蛋白酶(嗜热解蛋白菌素)直接加入所述弹性蛋白水混合液中。嗜热菌蛋白酶含有约60%的蛋白(60.2%),约13%(13.2%)的醋酸钠,和约25%(25.3%)的醋酸钙,特定活性约8.720I.U/毫克干重。弹性蛋白肽水混合物的pH值用一个pH仪或者pH计监测,并且用10%的甲胺调节使pH值保持在6.8至7.5之间。消解能够连续75分钟,然后加浓盐酸把pH值调整到3.0以终止消解。
消解终止以后,消解产物优选地经PM10 Diaflow10000分子量阻断超滤膜过滤,以滤掉所有的超过10,000道尔顿分子量的蛋白或者肽。产生的上清液是得到的组合物,含有分子量低于约10,000道尔顿的肽。事实表明,最优选的组合物是分子量低于1,000道尔顿的弹性蛋白肽。表1是从热裂解弹性蛋白分离出的肽片序列。这些分离出来的片段,不论是单独的还是组合的,在施加于组织时,使得组织,特别是哺乳动物的皮肤显示皮肤弹性增加的特点,包括皮肤的柔性和增加丰满度,以及整体增加了皮肤的媚力。从下面的表1可见,优选地,本发明的组合物含有氨基酸链长少于10个氨基酸的弹性蛋白肽片段,或者具有分子量在约150-800道尔顿的范围,更优选地在约180-600道尔顿的范围,最优选地,所述治疗性或者美容性的组合物包括分子量约188-585道尔顿范围的弹性蛋白片段。还优选的是,配制本发明的组合物所用的肽实质上由具有非极化的和/或不带电荷的侧基(也就是丙氨酸、缬氨酸、脯氨酸、甘氨酸)的氨基酸组成,更优选地由包括缬氨酸或者脯氨酸的肽构成,更加优选地由每个氨基酸序列中都含有缬氨酸和脯氨酸的肽组成。
本发明中确定的弹性蛋白肽片段具有以下的氨基酸序列:
表1
序列# | 肽 | 分子量 | 名称(N-至C-末端) | c-DNA 拷贝 |
1. | AVG | 245 | 丙氨酸-缬氨酸-甘氨酸 | 1 |
2. | VGAG | 302 | 缬氨酸-甘氨酸-丙氨酸-甘氨酸 | 2 |
3. | IGG | 302 | 异亮氨酸-甘氨酸-甘氨酸 | 4 |
4. | LG | 188 | 亮氨酸-甘氨酸 | 26 |
5. | IGAG | 316 | 异亮氨酸-甘氨酸-丙氨酸-甘氨酸 | 2 |
6. | LGG | 245 | 亮氨酸-甘氨酸-甘氨酸 | 6 |
7. | VAPG | 342 | 缬氨酸-丙氨酸-脯氨酸-甘氨酸 | 2 |
8. | LGPG | 342 | 亮氨酸-甘氨酸-脯氨酸-甘氨酸 | 3 |
9. | LGAG | 316 | 亮氨酸-甘氨酸-丙氨酸-甘氨酸 | 4 |
10. | VGPG | 328 | 缬氨酸-甘氨酸-脯氨酸-甘氨酸 | 2 |
11. | FGPG | 376 | 苯丙氨酸-甘氨酸-脯氨酸-甘氨酸 | 2 |
12. | VGPQ | 399 | 缬氨酸-甘氨酸-脯氨酸-谷氨酰胺 | 1 |
13. | LGA | 259 | 亮氨酸-甘氨酸-丙氨酸 | 7 |
14. | VGPA | 342 | 缬氨酸-甘氨酸-脯氨酸-丙氨酸 | 1 |
15. | VVPG | 370 | 缬氨酸-缬氨酸-脯氨酸-甘氨酸 | 2 |
16. | AVPG | 342 | 丙氨酸-缬氨酸-脯氨酸-甘氨酸 | 2 |
17. | VVPG | 441 | 缬氨酸-缬氨酸-脯氨酸-谷氨酰胺 | 1 |
18. | VAARPG | 569 | 缬氨酸-丙氨酸-丙氨酸-精氨酸-脯氨酸-甘氨酸 | 1 |
19. | LGAGGAG | 501 | 亮氨酸-甘氨酸-丙氨酸-甘氨酸-甘氨酸-丙氨酸-甘氨酸 | 1 |
20 | AIPG | 356 | 丙氨酸-异亮氨酸-脯氨酸-甘氨酸 | 2 |
21. | LGPGG | 399 | 亮氨酸-甘氨酸-脯氨酸-甘氨酸-甘氨酸 | 1 |
22. | AAAQA | 430 | 丙氨酸-丙氨酸-丙氨酸-谷氨酰胺-丙氨酸 | 1 |
23. | VGVHypG | 444 | 缬氨酸-甘氨酸-缬氨酸-羟脯氨酸-甘氨酸 | 14<sup>*</sup> |
24. | VYPGG | 491 | 缬氨酸-酪氨酸-脯氨酸-甘氨酸-甘氨酸 | 1 |
25. | IGGVGG | 458 | 异亮氨酸-甘氨酸-甘氨酸-缬氨酸-甘氨酸-甘氨酸 | 1 |
26. | VAPGVG | 498 | 缬氨酸-丙氨酸-脯氨酸-甘氨酸-缬氨酸-甘氨酸 | 1 |
27. | LGVGG | 401 | 亮氨酸-甘氨酸-缬氨酸-甘氨酸-甘氨酸 | 3 |
28. | VLPG | 384 | 缬氨酸-亮氨酸-脯氨酸-甘氨酸 | 3 |
29. | FRAAA | 534 | 苯丙氨酸-精氨酸-丙氨酸-丙氨酸-丙氨酸 | 1 |
30. | VGGVPG | 484 | 缬氨酸-甘氨酸-甘氨酸-缬氨酸-脯氨酸-甘氨酸 | 1 |
31. | FGPGG | 433 | 苯丙氨酸-甘氨酸-脯氨酸-甘氨酸-甘氨酸 | 1 |
32. | VGVPG | 427 | 缬氨酸-甘氨酸-缬氨酸-脯氨酸-甘氨酸 | 4<sup>*</sup> |
33. | VLPGAG | 512 | 缬氨酸-亮氨酸-脯氨酸-甘氨酸-丙氨酸-甘氨酸 | 1 |
34. | VGLHypG | 458 | 缬氨酸-甘氨酸-亮氨酸-羟脯氨酸-甘氨酸 | 1<sup>**</sup> |
35. | LGVGA | 415 | 亮氨酸-甘氨酸-缬氨酸-甘氨酸-丙氨酸 | 1 |
36. | AFPG | 390 | 丙氨酸-苯丙氨酸-脯氨酸-甘氨酸 | 1 |
37. | AFPGA | 461 | 丙氨酸-苯丙氨酸-脯氨酸-甘氨酸-丙氨酸 | 1 |
38. | VGIPA | 455 | 缬氨酸-甘氨酸-异亮氨酸-脯氨酸-丙氨酸 | 1 |
39. | VGGIPT | 542 | 缬氨酸-甘氨酸-甘氨酸-异亮氨酸脯氨酸-苏氨酸 | 无 |
40. | VGVGVPG | 583 | 缬氨酸-甘氨酸-缬氨酸-甘氨酸-缬氨酸-脯氨酸-甘氨酸 | 2 |
41. | LGPGVG | 498 | 亮氨酸-甘氨酸-脯氨酸-甘氨酸-缬氨酸-甘氨酸 | 1 |
*序列23和序列32看来是共同序列,因为脯氨酸羟化是转录后事件。
**同VGLPG
以上序列占所有弹性蛋白序列的约40%,其它序列下降到没有氨基酸或锁链素交联(这些氨基酸没有计入排序)。
由嗜热菌蛋白酶消解所获得的弹性蛋白肽片段/水混合物,优选快速地蒸发干燥并且重新溶入少量的蒸馏水而且希望时用蒸馏水充分稀释以利于冷冻干燥。变通地,不去重新溶解弹性蛋白肽,而是把过滤后的产物冷冻干燥两次,得到含有30重量化学连接水和很少的盐(NaCl)。优选地,用于治疗的粉末溶解至浓度为0.0002%至90%重量的弹性蛋白肽片段范围,更优选地在约0.05%至约50%范围,再优选地在约0.05%至约10%的弹性蛋白肽片段范围,还要优选地为约1.5%弹性蛋白肽片段,最优选地为约1.3%的肽片段,或者适用于局部或者皮下给药的赋形剂中的片段。
如图1所示,用包括肽片段的组合物的局部治疗,在以约1.3%的浓度施加于斯普拉道来氏雄大鼠皮肤一个月时间以上,展示皮肤的弹性蛋白含量,与对照组和与同样方法和浓度施用DHEA相比都高一倍。图1中S CONTR代表刮毛的对照,US CONTR代表不刮毛的对照,图1显示本发明有通过增加皮肤内的内源性弹性蛋白产物有加强皮肤的柔性或者弹性的优良性质。本发明的肽和其制剂还改善皮肤的纹理,尤其是通过改善弹性蛋白的内源性生成而改善皮肤的物理表观。
本发明的肽和制剂的给药方法采用任何数量的公知的给药途径,如口服、静脉内给药、皮下给药、经皮给药和局部给药。本发明的一种优选方法采用一种药学的或者美容组合物,该组合物改善皮肤的物理表观和/或组织的弹性。据信,弹性蛋白肽片段穿透皮肤的限度为约20,000道尔顿分子量。优越地,本发明还涉及通过热裂解得到的肽,其分子量低于10,000道尔顿,更优选地低于约3,000道尔顿,再更加优选地低于约1,000道尔顿。因此本发明的肽显得满足在施用时被皮肤吸收的标准****,除了因为本发明的活性肽尺寸相对较小而增加吸收之外,肽本身优选地与经嗜热菌蛋白酶热裂解弹性蛋白形成的肽对应,显示活性加大。据认为,活性至少部分地因为在用药或者施加组合物的皮肤上产生内源性弹性蛋白。
本发明可以配制在数种载体赋形剂中,例如喷雾剂、气溶胶、水油型乳剂、油水型乳剂、面膏剂、体膏、日光浴剂或者日光浴后洗剂或其它局部用药赋形剂。前面提到的美国专利4,327,078是不同的局部用药的例子,可以用于使用可溶的弹性蛋白衍生物。在所提供的各个例中,本发明的弹性蛋白肽片段的浓度优选地约1.5%,并增加水的含量以补差额。
本发明组合物的局部给药优选地在预定的时间内重复地进行,优选在一个星期到一个月的范围内。用于进行图1的试验的斯普拉道来氏大鼠中,大鼠用1.3%浓度的本文公开的方法配制的亲水弹性蛋白肽局部处理30天。试验表明每个给药的大鼠的内源性弹性蛋白(以每毫克脱脂干重皮肤微克弹性蛋白测算),与对照组和在同样的时间内用5%的DHEA处理的大鼠比,多一倍。各用三只动物产生S OUNTR,USCONT,DHEA物数据,11只动物用于HEP的数据。从各个动物的治疗区域采取皮样用于研究,从各个动物得到的三个结果加以平均。平均值为:S OUNTR(1,408);US CONT(2.291);DHEA(1.753);HEP(3.175)。皮肤的弹性蛋白含量通过Sandberg等(″Quantitation ofElastin in Tissues and Culture:problems related to the accuratemeasurement of small amount of elastin with special emphasis on the rat″Connective Tissure Research.25:139-48,1990)中揭示了准确测量大鼠弹性蛋白的方法,此文的测量部分在本文中引作参考。通过方差分析确定的图1的数据中α值低于0.001是显著的,因为低于一千次中随机出现事件的机会低于一次。
图1的数据还支持把美容品或者药用制剂用一个延长的时间范围,优选地用一周到一个月的范围,更优选地用7至14天的范围,最优选地,在约14天中每天用约1,5%的浓度的分子量低于约10,000道尔顿,更优选地低于1,000道尔顿且最优选地在约180至约600道尔顿范围的弹性蛋白肽或者肽给药。
图2A-2D是显微照片,表示本发明的应用改进表观和有益美容。由图2A-2D可见,用弹性蛋白肽片段处理过的皮肤看上去比末处理过的皮肤健康。这在显微镜下表现在血管的响应上增加。图2A-2D中大鼠皮肤的固定组织部分用结合抗纤连蛋白抗体的荧光素标识。图2A是不刮毛的对照组织代表例;图2B是刮毛的对照组织代表例;图2C是用吸收的DHEA进行局部处理的组织代表例。最后,图2D是用本发明以按照以上关于图1讨论的例子进行的局部处理。对照组(图2A和图2B)中的皮层与图2C和图2D比相对地一致且薄。为了方便,在图2A、2B、2C和2D各图中,皮层均划出。令人惊异地,为了说明使用本发明所获得的好处,图2D显示皮下区域毛细血管密度增加。该图中毛细血管显示在皮层下的明亮的椭圆形色斑体。皮下区域内的内皮细胞密度的增加提示毛细血管密度增加,因此说明本发明的肽和制剂用于血管或者毛细血管形成(新血管形成或血管生成)方面的潜力。
看来本发明的弹性蛋白肽片段应优选地包括缬氨酸-缬氨酸-脯氨酸-谷氨酰胺序列或者缬氨酸-甘氨酸-缬氨酸-羟脯氨酸(可能是脯氨酸)-甘氨酸序列。还显示出,含有缬氨酸和/或脯氨酸的序列的序列也是优选的,并且,高浓度(相对于其中的其它氨基酸而言)包含此两者之一或者两者的氨基酸是最优选的。
由下面的表II可知,看来某些本说明所述的肽组(例如包括1号至41号序列)在关系到用作美容或者皮肤的治疗施用方面有优选的特性。由嗜热菌蛋白酶消解弹性蛋白分离出的弹性蛋白肽混合物(即包括1号至41号序列)在出HPLC(高压液相色谱)时加以收集。不去个别地分离每个嗜热菌蛋白酶肽片段,而是在5至50分钟的范围内收集5个肽片段或者簇,然后用溴脱氧三磷酸(BrdUTP)合体作用测量检测活性。测量mRNA的方法包括蛋白合成。表II测量绿色荧光密度以测度联用弹性蛋白片段处理后RFL-6细胞中mRNA增加的疗效。
表II
馏份# | 大约的洗提时间 | 大约的减去对照的重量%变化 |
123456 | 5.3-11.8分钟11.8-23.0分钟23.0-44.1分钟44.1-45.8分钟45.8-50.0分钟没有分开成的馏份(1-14号序列) | 1%4%41%10%2%52% |
每个馏份都表现RFL-6细胞中的mRNA比对照组增加了。然而,由检测可见,只用馏份#3和/或与其它馏份联合(例如由馏份#6可见)作为组合物或者说制剂以增加组织,尤其是皮肤的弹性、丰满度和/或表观有良好的潜力。馏份3包括14至31号序列。应当注意到鉴于要得到分不开馏份的混合物(如上讨论),更优选地使用分不开馏份的混合物,而不是去分离更有活性的成分。
馏份或者簇3按照HPCL上分辨的10个主要峰(在215纳米)再分开成10个子馏份。下面的表III表示绿色荧光密度作为对上面的表II中所示的馏份3的10个子馏份疗效的RFL-6细胞中mRNA增加的测定。
表III
馏份# | 本文中专利序列号 | 缩写肽序列 | 绿色荧光强度%变化 |
123456 | 序列号14序列号15、16序列号17序列号18、19序列号20、21序列号22 | VGPAVVPG,AVPGVVPQVAARPG、LGAGGAGAIPG、LGPGGAAAQA | 394085444220 |
78910空白 | 序列号23序列号24序列号25、26、27、28、29序列号30、31 | VGVHypGVYPGGIGGVGG、VAPGVGLGVGG、VLPG、FRAAAVGGVPG、FGPGG23 | 57381030 |
如表III清楚可见,序列17(VVPQ)活性最大,依次往下为序列23(VGVHypG)、序列18(VAARPG)和序列19(LGAGGAG)。看来,序列22和25-31实际上对馏份3的总体治疗或者美容价值起不利的影响。但是本申请人不想拘泥于这种看法,认为这些馏份的任何一个或者组合在降低馏份样品的绿色荧光强度的同时事实上会增加用总的混合物或者在与其它的肽结合使用(例如,任何1-41分别地)时所希望的特点。
尽管上文进行了详细说明,这些序列是为了说明举出的,而不是为了限制。以上公开的技术的改性和改进,包括等价物,是在本领域内的一般技术人员的范围和能力之内的,包括在本文所附的权利要求书的范围内。对于本领域内的一般技术人员可以容易看到,对以上的说明可以作出许多修改、变化和改变而不偏离本文说明的概念。例如,所述肽和制剂可以经本领域内公知的给药赋形剂的方式给药,而所述肽可以由肽消解得到,或者从氨基酸排序得到(不论固体状态还是液体状态),以及由细菌系统过度表达得到。修改(不论化学的还是酶的)以上所述的基本序列也包括在本发明的范围内。例如,看来,弹性蛋白序列中重现式样是甘氨酸-丙氨酸残基的表现。因此序列1-41可以修改为包括这种残基,不论是肽的氨基还是羧基末端。所述序列还可以化学改性以增加其活性(例如,把序列的羧基末端部分酰胺化)。因此,所有这些变化都应当视作下面的权利要求书中规定的本发明的范围内。
序列表
(1)一般资料
(I)申请人:Sanderg,lawrence;Roos,Phillip;Mitts,Thomas
(II)发明名称:肽组合物和制剂及其使用
(III)序列数量:41
(IV)通信地址:
(A)地址:REED SMITH SHAW & MCCLAY,LLP
(B)街道:448号信箱
(C)城市:Pittsburgh
(D)州名:Pennsylvania:
(E)国家:美国
(F)邮政编码:15230
(V)计算机可机读形式
(A)媒介类型:3.5英寸盘,1.44Mb
(B)计算机:康柏
(C)操作系统:Microsoft Windows 95
(D)软件:Word6.0
(VI)当前的申请资料;
(A)申请号:
(B)归档日期:1999年3月12日
(C)类别:
(VIII)专利律师/代理事务所资料
(A)姓名:Miller,Raymond A.
(B)注册号:42,891
(C)证明/诉讼号:97-489-WO
(IX)通信资料:
(A)电话:(412)288-4192
(B)电传:(412)288-3300
(2)Seq ID NO.1资料:
(I)序列特征:
(A)长度:3个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.1:
Ala Val Gly
1
(2)Seq ID NO.2资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.2:
Val Gly Ala Gly
l
(2)Seq ID NO.3资料:
(I)序列特征:
(A)长度:3个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.3:
Ile Gly Gly
1
(2)Seq ID NO.4资料:
(I)序列特征:
(A)长度:2个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.4:
Leu Gly
1
(2)Seq ID NO.5资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.5:
Ile Gly Ala Gly
1
(2)Seq lD NO.6资料:
(I)序列特征:
(A)长度:3个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.6:
Leu Gly Gly
1
(2)Seq ID NO.7资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.7:
Val Ala Pro Gly
1
(2)Seq ID NO.8资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.8:
Leu Gly Pro Gly
1
(2)Seq ID NO.9资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.9:
Leu Gly Ala Gly
1
(2)Seq ID NO.10资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.10:
Val Gly Pro Gly
1
(2)Seq ID NO.11资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.11:
Phe Gly Pro Gly
1
(2)Seq ID NO.12资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.12:
Val Gly Pro Gln
1
(2)Seq ID NO.13资料:
(I)序列特征:
(A)长度:3个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.13:
Leu Gly Ala
1
(2)Seq ID NO.14资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.14:
Val Gly Pro Ala
1
(2)Seq ID NO.15资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.15:
Val Val Pro Gly
1
(2)Seq ID NO.16资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.16:
Ala Val Pro Gly
1
(2)Seq ID NO.17资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.17:
Val Val Pro Gln
1
(2)Seq ID NO.18资料:
(I)序列特征:
(A)长度:6个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.18:
Val Ala Ala Arg Pro Gly
1 5
(2)Seq ID NO.19资料:
(I)序列特征:
(A)长度:7个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.19:
Leu Gly Ala Gly Gly Ala Gly
1 5
(2)Seq ID NO.20资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.20:
Ala Ile Pro Gly
1
(2)Seq ID NO.21资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.21:
Leu Gly Pro Gly Gly
1 5
(2)Seq ID NO.22资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.22:
Ala Ala Ala Gln Ala
1 5
(2)Seq ID NO.23资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.23:
Val Gly Val Xaa Gly
1 5
(2)Seq ID NO.24资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.24:
Val Tyr Pro Gly Gly
1 5
(2)Seq ID NO.25资料:
(I)序列特征:
(A)长度:6个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.25:
Ile Gly Gly Val Gly Gly
1 5
(2)Seq ID NO.26资料:
(I)序列特征:
(A)长度:6个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.26:
Val Ala Pro Gly Val Gly
1 5
(2)Seq ID NO.27资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.27:
Leu Gly Val Gly Gly
1 5
(2)Seq ID NO.28资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.28:
Val Leu Pro Gly
1
(2)Seq ID NO.29资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.29:
Phe Arg Ala Ala Ala
1 5
(2)Seq ID NO.30资料:
(I)序列特征:
(A)长度:6个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.30:
Val Gly Gly Val Pro Gly
1 5
(2)Seq ID NO.31资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.31:
Phe Gly Pro Gly Gly
1 5
(2)Seq ID NO.32资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.32:
Val Gly Val Pro Gly
1 5
(2)Seq ID NO.33资料:
(I)序列特征:
(A)长度:6个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.33:
Val Leu Pro Gly Ala Gly
1 5
(2)Seq ID NO.34资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.34:
Val Gly Leu Xaa Gly
1 5
(2)Seq ID NO.35资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.35:
Leu Gly Val Gly Ala
1 5
(2)Seq ID NO.36资料:
(I)序列特征:
(A)长度:4个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.36:
Ala Phe Pro Gly
1
(2)Seq ID NO.37资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.37:
Ala Phe Pro Gly Ala
1 5
(2)Seq ID NO.3 8资料:
(I)序列特征:
(A)长度:5个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.38:
Val Gly Ile Pro Ala
1 5
(2)Seq ID NO.39资料:
(I)序列特征:
(A)长度:6个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.39:
Val Gly Gly Ile Pro Thr
1 5
(2)Seq ID NO.40资料:
(I)序列特征:
(A)长度:7个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.40:
Val Gly Val Gly Val Pro Gly
1 5
(2)Seq ID NO.41资料:
(I)序列特征:
(A)长度:6个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑学:线形
(II)分子类型:肽
(XI)序列描述:Seq ID NO.41:
Leu Gly Pro Gly Val Gly
1 5
Claims (25)
1.适用于哺乳动物组织处理的组合物,所述组合物含有选自以下序列的至少一种弹性蛋白肽片段:序列14、序列15、序列16、序列17、序列18、序列19、序列20、序列21、序列22、序列23、序列24、序列25、序列26、序列27、序列28、序列29、序列30和序列31。
2.根据权利要求1的组合物,其中所述弹性蛋白肽片段可溶于水溶液。
3.根据权利要求1的组合物,其中所述弹性蛋白肽片段为治疗有效浓度。
4.根据权利要求1的组合物,其中所述弹性蛋白肽片段选自:序列17、序列18、序列19和序列23。
5.根据权利要求1的组合物,其中所述弹性蛋白肽片段选自:序列14、序列15、序列16、序列17、序列18、序列19、序列20、序列21、序列23和序列24。
6.根据权利要求1的组合物,其中所述弹性蛋白肽片段的序列是序列17。
7.根据权利要求1的组合物,其中所述弹性蛋白肽片段的序列是序列19。
8.根据权利要求1的组合物,其中所述弹性蛋白肽片段的序列是序列23。
9.根据权利要求1的组合物,其中所述弹性蛋白肽片段的序列是序列18。
10.根据权利要求1的组合物,其中所述弹性蛋白肽片段的分子量低于约1000道尔顿。
11.根据权利要求1的组合物,其中所述弹性蛋白肽片段通过用嗜热菌蛋白酶消解弹性蛋白形成。
12.根据权利要求1的组合物,其中所述弹性蛋白肽片段按重量计占约0.0002%到约90%的范围。
13.根据权利要求1的组合物,其中所述弹性蛋白肽片段按重量计占约0.5%到约10%的范围。
14.根据权利要求1的组合物,其中所述组合物是美容品制剂。
15.根据权利要求1的组合物,其中所述受处理的哺乳动物组织是血管。
16.根据权利要求1的组合物,其中所述组合物适用于治疗选自下列的病情:高血压、冠心病、动脉粥样硬化、心绞疼、冠状动脉血栓、慢性阻塞性肺病和血管成形术后阻塞。
17.根据权利要求14的组合物,其中所述美容品制剂还包括一种给药系统。
18.根据权利要求17的组合物,其中所述给药系统选自局部给药系统和皮下给药系统。
19.根据权利要求18的组合物,其中所述局部给药系统选自:粉末、乳剂、洗剂、喷雾剂、油剂、气溶胶、膏剂和泡沫。
20.根据权利要求1的药用组合物,其中所述弹性蛋白肽片段的序列是序列14。
21.根据权利要求1的药用组合物,其中所述弹性蛋白肽片段的序列是序列15。
22.根据权利要求1的药用组合物,其中所述弹性蛋白肽片段的序列是序列16。
23.根据权利要求1的药用组合物,其中所述弹性蛋白肽片段的序列是序列20。
24.根据权利要求1的药用组合物,其中所述弹性蛋白肽片段的序列是序列21。
25.根据权利要求1的药用组合物,其中所述弹性蛋白肽片段的序列是序列24。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/039,308 US6069129A (en) | 1998-03-13 | 1998-03-13 | Elastin derived composition and method of using same |
US09/039,308 | 1998-03-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1300220A CN1300220A (zh) | 2001-06-20 |
CN100364606C true CN100364606C (zh) | 2008-01-30 |
Family
ID=21904781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998059390A Expired - Fee Related CN100364606C (zh) | 1998-03-13 | 1999-03-12 | 肽组合物和制剂及其使用 |
Country Status (19)
Country | Link |
---|---|
US (2) | US6069129A (zh) |
EP (1) | EP1064010B1 (zh) |
JP (1) | JP2002506041A (zh) |
KR (1) | KR100612535B1 (zh) |
CN (1) | CN100364606C (zh) |
AP (1) | AP2000001905A0 (zh) |
AT (1) | ATE386536T1 (zh) |
AU (1) | AU765379B2 (zh) |
BR (1) | BR9908749A (zh) |
CA (1) | CA2322839A1 (zh) |
DE (1) | DE69938174T2 (zh) |
EA (1) | EA003857B1 (zh) |
HK (1) | HK1036225A1 (zh) |
ID (1) | ID28270A (zh) |
IL (2) | IL138453A0 (zh) |
NO (1) | NO325371B1 (zh) |
NZ (1) | NZ506898A (zh) |
OA (1) | OA11531A (zh) |
WO (1) | WO1999045941A1 (zh) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962904B1 (en) * | 1998-03-13 | 2005-11-08 | Connective Tissue Imagineering | Elastin peptide analogs and uses thereof |
US6809075B1 (en) * | 2000-05-30 | 2004-10-26 | Connective Tissue Imagineering Llc | Elastin peptide analogs and uses of same incombination with skin enhancing agents |
US6777389B1 (en) * | 1998-11-19 | 2004-08-17 | Connective Tissue Imagineering Llc | Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides |
US6903244B1 (en) * | 1999-02-26 | 2005-06-07 | University Of Utah Research Foundation | Mice which are +/− or −/− for the elastin gene as models for vascular disease |
EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US6794362B1 (en) * | 2000-05-30 | 2004-09-21 | Connective Tissue Imagineering Llc | Asparagine containing elastin peptide analogs |
AU2001275018B2 (en) * | 2000-05-30 | 2008-04-03 | Connective Tissue Imagineering Llc | Composition and method for enhancing elasticity of tissue |
SG98420A1 (en) * | 2000-07-13 | 2003-09-19 | Purzer Pharmaceutical Co Ltd | Method for transferring one or more active ingredients between different phase carriers |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
US20030198631A1 (en) * | 2002-04-18 | 2003-10-23 | Healthpoint, Ltd. | Thermolysin enzymatic wound debrider |
US7560430B2 (en) | 2003-02-14 | 2009-07-14 | Human Matrix Sciences, Llc | Elastin digest compositions and methods utilizing same |
FR2854897B1 (fr) * | 2003-05-12 | 2007-05-04 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane. |
US6927206B2 (en) * | 2003-06-06 | 2005-08-09 | Procyte Corporation | Compositions and methods for treatment of rosacea |
GB0313644D0 (en) * | 2003-06-12 | 2003-07-16 | Univ Bristol | Inhibition of infection |
US20050063932A1 (en) * | 2003-08-14 | 2005-03-24 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
US20060198800A1 (en) * | 2003-08-14 | 2006-09-07 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
US7803522B2 (en) * | 2004-02-13 | 2010-09-28 | Human Matrix Sciences, Llc | Elastin producing fibroblast formulations and methods of using the same |
EP1725245B1 (en) | 2004-02-20 | 2012-01-25 | Human Matrix Sciences, LLC | Manganese and iron based compounds for elastogenesis and connective tissue treatment |
US7392611B2 (en) * | 2004-12-22 | 2008-07-01 | Smith & Wesson Corp. | Apparatus and method for firearm takedown |
US8114829B2 (en) * | 2005-02-22 | 2012-02-14 | Human Matrix Sciences, Llc | Elastin protective polyphenolics and methods of using the same |
US8642578B2 (en) | 2005-03-29 | 2014-02-04 | Human Matrix Sciences, Llc | Elastin protective polyphenolics and methods of using the same |
CA2608747C (en) | 2005-05-17 | 2013-01-22 | Human Matrix Sciences, Llc | Elastin producing fibroblast formulations and methods of using the same |
JP2007045722A (ja) * | 2005-08-08 | 2007-02-22 | Kyushu Institute Of Technology | 水溶性エラスチンとそれを含む食品及び医薬 |
JP2009537492A (ja) | 2006-05-15 | 2009-10-29 | ヴァリオ・リミテッド | 治療上有用なペプチドの新規用途 |
US8778376B2 (en) | 2006-06-09 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating |
JP5276813B2 (ja) * | 2006-08-25 | 2013-08-28 | 日本ハム株式会社 | エラスチン分解ペプチド並びにエラスチン及びその酵素分解ペプチドの製造方法 |
US8828354B2 (en) | 2008-03-27 | 2014-09-09 | Warsaw Orthopedic, Inc. | Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US8956636B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprosing ketorolac |
US9125917B2 (en) | 2008-04-18 | 2015-09-08 | Warsaw Orthopedic, Inc. | Fluocinolone formulations in a biodegradable polymer carrier |
US9132085B2 (en) | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
US9289409B2 (en) * | 2008-04-18 | 2016-03-22 | Warsaw Orthopedic, Inc. | Sulindac formulations in a biodegradable material |
US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US9132119B2 (en) | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US8956641B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US20090263451A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US8557273B2 (en) * | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
US20090264478A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Sulfasalazine formulations in a biodegradable polymer carrier |
US20100015049A1 (en) * | 2008-07-16 | 2010-01-21 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
US9492375B2 (en) | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
JP2010155820A (ja) * | 2008-10-10 | 2010-07-15 | Hayashikane Sangyo Kk | 皮膚改善剤、血管改善剤、並びにこれらを含む医薬組成物、食品、飼料及び化粧品 |
US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
US9161903B2 (en) | 2008-10-31 | 2015-10-20 | Warsaw Orthopedic, Inc. | Flowable composition that hardens on delivery to a target tissue site beneath the skin |
US8980317B2 (en) * | 2008-12-23 | 2015-03-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating infections comprising a local anesthetic |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
US20100226959A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Matrix that prolongs growth factor release |
US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
US8617583B2 (en) | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
US8653029B2 (en) | 2009-07-30 | 2014-02-18 | Warsaw Orthopedic, Inc. | Flowable paste and putty bone void filler |
US8231891B2 (en) | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
US20110097380A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Clonidine formulations having antimicrobial properties |
US9504698B2 (en) * | 2009-10-29 | 2016-11-29 | Warsaw Orthopedic, Inc. | Flowable composition that sets to a substantially non-flowable state |
US8597192B2 (en) | 2009-10-30 | 2013-12-03 | Warsaw Orthopedic, Inc. | Ultrasonic devices and methods to diagnose pain generators |
US8475824B2 (en) * | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
US8758791B2 (en) * | 2010-01-26 | 2014-06-24 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
US9486500B2 (en) | 2010-01-28 | 2016-11-08 | Warsaw Orthopedic, Inc. | Osteoimplant and methods for making |
US9125902B2 (en) * | 2010-01-28 | 2015-09-08 | Warsaw Orthopedic, Inc. | Methods for treating an intervertebral disc using local analgesics |
US9050274B2 (en) * | 2010-01-28 | 2015-06-09 | Warsaw Orthopedic, Inc. | Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents |
US8246571B2 (en) | 2010-08-24 | 2012-08-21 | Warsaw Orthopedic, Inc. | Drug storage and delivery device having a retaining member |
JP6083085B2 (ja) * | 2010-09-08 | 2017-02-22 | 国立大学法人九州工業大学 | アンジオテンシン変換酵素阻害剤およびその用途 |
US8740982B2 (en) | 2010-10-26 | 2014-06-03 | Kyphon Sarl | Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis |
US9414930B2 (en) | 2010-10-26 | 2016-08-16 | Kyphon SÀRL | Activatable devices containing a chemonucleolysis agent |
US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
US8623396B2 (en) | 2010-12-03 | 2014-01-07 | Warsaw Orthopedic, Inc. | Compositions and methods for delivering clonidine and bupivacaine to a target tissue site |
WO2012075451A2 (en) | 2010-12-03 | 2012-06-07 | Warsaw Orthopedic, Inc. | Clonidine and gaba compounds in a biodegradable polymer carrier |
US9060978B2 (en) | 2011-01-24 | 2015-06-23 | Warsaw Orthopedic, Inc. | Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist |
US9717779B2 (en) | 2011-01-31 | 2017-08-01 | Warsaw Orthopedic, Inc. | Implantable matrix having optimum ligand concentrations |
DK2683393T3 (en) * | 2011-02-11 | 2018-07-23 | Univ Michigan Regents | TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES |
US9511077B2 (en) | 2011-04-25 | 2016-12-06 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an anabolic agent for wound healing |
US9592243B2 (en) | 2011-04-25 | 2017-03-14 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an anabolic agent for treatment of an injury |
US9205241B2 (en) | 2011-07-12 | 2015-12-08 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an adhesive material |
US9132194B2 (en) | 2011-07-12 | 2015-09-15 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an adhesive sheet containing a drug depot |
US9511018B2 (en) | 2012-04-05 | 2016-12-06 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable matrix |
US8735504B2 (en) | 2012-05-02 | 2014-05-27 | Warsaw Orthopedic, Inc. | Methods for preparing polymers having low residual monomer content |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US9764122B2 (en) | 2014-07-25 | 2017-09-19 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having an occluding member |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
KR101706296B1 (ko) | 2015-12-21 | 2017-02-13 | 주식회사 브레인온 | 기억력, 학습력, 인지력 향상용 조성물 |
MX2018006823A (es) | 2015-12-21 | 2018-11-29 | Brainon Inc | Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva. |
US10549081B2 (en) | 2016-06-23 | 2020-02-04 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
CN107890116B (zh) * | 2016-10-04 | 2023-01-10 | 株式会社Lg生活健康 | 亮氨酸衍生物、包含其的组合物及其用途 |
KR102504364B1 (ko) * | 2016-10-04 | 2023-02-28 | 주식회사 엘지생활건강 | 류신 유도체, 이를 포함하는 조성물 및 이의 용도 |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
KR102007079B1 (ko) * | 2017-03-24 | 2019-10-02 | (주)셀아이콘랩 | 펩타이드를 활용한 피부의 노화 억제용 조성물 및 세포노화 억제와 주름개선을 위한 화장품 조성물 |
GB201711360D0 (en) | 2017-07-14 | 2017-08-30 | Raft Entpr Ltd | Tissue scaffold |
JP2019112401A (ja) * | 2017-12-22 | 2019-07-11 | 株式会社バイタルリソース応用研究所 | アンジオテンシン変換酵素阻害化合物 |
CN108261539A (zh) * | 2018-02-27 | 2018-07-10 | 南京圣诺生物科技实业有限公司 | 一种用于抗血栓的组合物、其制备方法及用途 |
CN108588155A (zh) * | 2018-04-18 | 2018-09-28 | 珀莱雅化妆品股份有限公司 | 一种酶解猪动脉血管制备弹力蛋白肽的方法 |
US20230234986A1 (en) * | 2020-05-22 | 2023-07-27 | Sunshine Biopharma Inc. | Inhibitors of coronavirus protease |
FR3116273B1 (fr) * | 2020-11-17 | 2023-10-27 | Sederma Sa | Tétrapeptides, compositions les comprenant et leur utilisation cosmétique |
KR20230047692A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR102484277B1 (ko) * | 2021-11-22 | 2023-01-04 | 대한켐텍 주식회사 | 피부 미용 개선용 원료 조성물의 제조방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179333A (en) * | 1977-02-11 | 1979-12-18 | Firma Carl Freudenberg | Method for making water-soluble elastin hydrolyzates |
US5523291A (en) * | 1993-09-07 | 1996-06-04 | Datascope Investment Corp. | Injectable compositions for soft tissue augmentation |
US5648209A (en) * | 1994-06-09 | 1997-07-15 | Centre National De La Recherche Scientifique-Cnrs | Specific peptide fragment of the feline immunodeficiency virus (FIV), and its use as a diagnostic reagent |
JP2012225594A (ja) * | 2011-04-21 | 2012-11-15 | Panasonic Corp | 製氷装置 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7713618A (nl) * | 1976-12-11 | 1978-06-13 | Bayer Ag | Werkwijze voor de bereiding van een cosmetisch preparaat. |
US4591501A (en) * | 1981-04-13 | 1986-05-27 | Seton Company | Cosmetic and pharmaceutical sheet material containing polypeptides |
US4474763A (en) * | 1982-07-07 | 1984-10-02 | Lubowe Irwin I | Skin preparation |
US4659740A (en) * | 1985-02-14 | 1987-04-21 | Polydex Pharmaceuticals Ltd. | Cosmetic preparations comprising novel elastin derivatives |
US5223420A (en) * | 1985-03-01 | 1993-06-29 | Institut National De La Sante Et De La Recherche Medicale | Elastin-based product, a procedure for its preparation and its biological applications; in particular as biomaterials and artificial supports |
US5017691A (en) * | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
JP2549118B2 (ja) * | 1987-05-30 | 1996-10-30 | 三省製薬株式会社 | 乳化組成物 |
US5079003A (en) * | 1990-03-14 | 1992-01-07 | Adelia Scaffidi | Skin lotions and creams |
JP2863898B2 (ja) * | 1995-02-21 | 1999-03-03 | 末綱 陽子 | 新規なペプチドおよび免疫賦活剤 |
US5945409A (en) * | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
-
1998
- 1998-03-13 US US09/039,308 patent/US6069129A/en not_active Expired - Fee Related
-
1999
- 1999-03-12 CN CNB998059390A patent/CN100364606C/zh not_active Expired - Fee Related
- 1999-03-12 BR BR9908749-9A patent/BR9908749A/pt not_active Application Discontinuation
- 1999-03-12 EP EP99912486A patent/EP1064010B1/en not_active Expired - Lifetime
- 1999-03-12 DE DE69938174T patent/DE69938174T2/de not_active Expired - Fee Related
- 1999-03-12 EA EA200000933A patent/EA003857B1/ru unknown
- 1999-03-12 AU AU30854/99A patent/AU765379B2/en not_active Ceased
- 1999-03-12 NZ NZ506898A patent/NZ506898A/en unknown
- 1999-03-12 JP JP2000535355A patent/JP2002506041A/ja active Pending
- 1999-03-12 AT AT99912486T patent/ATE386536T1/de not_active IP Right Cessation
- 1999-03-12 IL IL13845399A patent/IL138453A0/xx active IP Right Revival
- 1999-03-12 AP APAP/P/2000/001905A patent/AP2000001905A0/en unknown
- 1999-03-12 OA OA1200000249A patent/OA11531A/en unknown
- 1999-03-12 ID IDW20002053A patent/ID28270A/id unknown
- 1999-03-12 CA CA002322839A patent/CA2322839A1/en not_active Abandoned
- 1999-03-12 WO PCT/US1999/005496 patent/WO1999045941A1/en active IP Right Grant
- 1999-03-12 KR KR1020007010112A patent/KR100612535B1/ko not_active IP Right Cessation
-
2000
- 2000-05-30 US US09/584,001 patent/US6506731B1/en not_active Expired - Fee Related
- 2000-09-12 NO NO20004540A patent/NO325371B1/no not_active IP Right Cessation
- 2000-09-13 IL IL138453A patent/IL138453A/en not_active IP Right Cessation
-
2001
- 2001-10-11 HK HK01107123A patent/HK1036225A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179333A (en) * | 1977-02-11 | 1979-12-18 | Firma Carl Freudenberg | Method for making water-soluble elastin hydrolyzates |
US5523291A (en) * | 1993-09-07 | 1996-06-04 | Datascope Investment Corp. | Injectable compositions for soft tissue augmentation |
US5648209A (en) * | 1994-06-09 | 1997-07-15 | Centre National De La Recherche Scientifique-Cnrs | Specific peptide fragment of the feline immunodeficiency virus (FIV), and its use as a diagnostic reagent |
JP2012225594A (ja) * | 2011-04-21 | 2012-11-15 | Panasonic Corp | 製氷装置 |
Non-Patent Citations (1)
Title |
---|
Quantitation of elastin through measurement of itspentapeptide content. Sandberg L B et al.Biochemical and Biophysicla research Communiction.,Vol.136 No.2. 1986 * |
Also Published As
Publication number | Publication date |
---|---|
NZ506898A (en) | 2003-05-30 |
IL138453A (en) | 2007-07-24 |
DE69938174D1 (de) | 2008-04-03 |
AU3085499A (en) | 1999-09-27 |
DE69938174T2 (de) | 2009-01-08 |
EP1064010B1 (en) | 2008-02-20 |
EP1064010A4 (en) | 2004-10-06 |
OA11531A (en) | 2004-05-06 |
AU765379B2 (en) | 2003-09-18 |
US6069129A (en) | 2000-05-30 |
NO20004540D0 (no) | 2000-09-12 |
EP1064010A1 (en) | 2001-01-03 |
CA2322839A1 (en) | 1999-09-16 |
ID28270A (id) | 2001-05-10 |
IL138453A0 (en) | 2001-10-31 |
NO325371B1 (no) | 2008-04-14 |
HK1036225A1 (en) | 2001-12-28 |
CN1300220A (zh) | 2001-06-20 |
KR100612535B1 (ko) | 2006-08-11 |
JP2002506041A (ja) | 2002-02-26 |
BR9908749A (pt) | 2001-10-09 |
KR20010041827A (ko) | 2001-05-25 |
US6506731B1 (en) | 2003-01-14 |
EA200000933A1 (ru) | 2001-04-23 |
ATE386536T1 (de) | 2008-03-15 |
NO20004540L (no) | 2000-11-09 |
EA003857B1 (ru) | 2003-10-30 |
AP2000001905A0 (en) | 2000-09-30 |
WO1999045941A1 (en) | 1999-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100364606C (zh) | 肽组合物和制剂及其使用 | |
KR102436084B1 (ko) | 신규 펩티드 및 이를 포함한 조성물 | |
US20110160137A1 (en) | Composition containing collagen peptide for improving skin care | |
CN103930125B (zh) | 具有失活rgd域的修饰的骨桥蛋白肽及其用途 | |
JP5247676B2 (ja) | 皮膚のトリートメントにおいて有用な合成ペプチド類および化粧品または皮膚薬剤組成物中でのその用途 | |
CN102166166B (zh) | 使用来自胎儿细胞及组织的化合物来改善皮肤状况的方法及其应用 | |
CN107400171A (zh) | 抗菌和促再矿化双效应防龋多肽、其衍生物和盐及应用 | |
NO179195B (no) | Topisk kosmetisk preparat | |
JP2004501976A (ja) | ペプチド組成物 | |
US7666842B2 (en) | Elastin peptide analogs and uses thereof | |
CN111961119B (zh) | 多肽在制备促进胶原蛋白分泌的药物或化妆品中的用途 | |
KR102543595B1 (ko) | 아미드화 아미노산을 포함하는 콜라겐 생성 촉진용 조성물 | |
MXPA00008979A (en) | Peptide compositions and formulations and use of same | |
Marimuthu et al. | Effects of Oral supplementation of trichovitalsTM on human skin, hair and Nail physiology | |
AU2007201615A1 (en) | Peptide compositions and formulations and use of same | |
AU2003270980A1 (en) | Peptide Compositions and Formulations and Use of Same | |
TWI356707B (en) | Methods and compositions using compounds from feta | |
NZ524930A (en) | Elastin peptide compositions and formulations and use of same | |
MXPA00007044A (en) | Cosmetic or dermatological use of 7-hydroxylated steroids alone and/or in combination with elastin derived peptides | |
KR20110074507A (ko) | 성장인자―유래 펩타이드 및 이의 용도 | |
KR20110076864A (ko) | 성장인자―유래 펩타이드 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1036225 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080130 Termination date: 20110312 |